Fibrates and coronary heart disease reduction in diabetes
- 1 August 2002
- journal article
- diabetes and-the-endocrine-pancreas-2
- Published by Wolters Kluwer Health in Current Opinion in Endocrinology, Diabetes and Obesity
- Vol. 9 (4) , 312-322
- https://doi.org/10.1097/00060793-200208000-00004
Abstract
Fibrates are peroxisome proliferator-activated receptor-α (PPARα) ligands with a broad range of lipid effects, in particular normalizing HDL and triglyceride metabolism in individuals with obesity and insulin resistance who have a high prevalence of type 2 diabetes and cardiovascular events. With diabetic dyslipidemia and obesity there is also an increased inflammatory response, endothelial dysfunction, and impaired fibrinolysis. In recent clinical trials with fibrates, there is emerging evidence for a selective and preferential effect of fibrates in reducing cardiovascular events independent of reducing LDL-C in subjects with a typical diabetic dyslipidemia who have an increased body weight and/or diabetes.Keywords
This publication has 107 references indexed in Scilit:
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetesDiabetic Medicine, 1997
- Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.Journal of Clinical Investigation, 1995
- Effects of Different Phenotypes of Hyperlipoproteinemia and of Treatment With Fibric Acid Derivatives on the Rates of Cholesterol 7α-Hydroxylation in HumansArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)The American Journal of Cardiology, 1993
- Change in LDL particle size is associated with change in plasma triglyceride concentration.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- Altering Triglyceride Concentrations Changes Insulin-Glucose Relationships in Hypertriglyceridemic Patients: Double-Blind Study With Gemfibrozil With Implications for AtherosclerosisDiabetes Care, 1991
- Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozilJournal of Internal Medicine, 1991
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Weight reduction increases adipose tissue lipoprotein lipase responsiveness in obese women.Journal of Clinical Investigation, 1987